Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Learn what scientific research and experts say about the evidence for common home remedies for herpes, including honey, lemon balm, and petroleum jelly.

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...

A recent international research project has used advanced microscopy techniques and computational modeling to discover why ...